- Home
- AVTX vs IOBT Comparison
AVTX vs IOBT Comparison
Compare AVTX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- IOBT
- Stock Information
- Founded
- AVTX 2011
- IOBT 2014
- Country
- AVTX United States
- IOBT Denmark
- Employees
- AVTX N/A
- IOBT N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- IOBT Health Care
- Exchange
- AVTX Nasdaq
- IOBT Nasdaq
- Market Cap
- AVTX 57.4M
- IOBT 62.6M
- IPO Year
- AVTX 2015
- IOBT 2021
- Fundamental
- Price
- AVTX $4.25
- IOBT $1.00
- Analyst Decision
- AVTX Strong Buy
- IOBT Strong Buy
- Analyst Count
- AVTX 6
- IOBT 3
- Target Price
- AVTX $34.20
- IOBT $9.33
- AVG Volume (30 Days)
- AVTX 66.4K
- IOBT 83.8K
- Earning Date
- AVTX 05-20-2025
- IOBT 05-20-2025
- Dividend Yield
- AVTX N/A
- IOBT N/A
- EPS Growth
- AVTX N/A
- IOBT N/A
- EPS
- AVTX N/A
- IOBT N/A
- Revenue
- AVTX $441,000.00
- IOBT N/A
- Revenue This Year
- AVTX N/A
- IOBT N/A
- Revenue Next Year
- AVTX N/A
- IOBT N/A
- P/E Ratio
- AVTX N/A
- IOBT N/A
- Revenue Growth
- AVTX N/A
- IOBT N/A
- 52 Week Low
- AVTX $4.15
- IOBT $0.66
- 52 Week High
- AVTX $16.00
- IOBT $1.79
- Technical
- Relative Strength Index (RSI)
- AVTX 31.02
- IOBT 52.54
- Support Level
- AVTX $4.80
- IOBT $0.95
- Resistance Level
- AVTX $5.26
- IOBT $1.20
- Average True Range (ATR)
- AVTX 0.45
- IOBT 0.09
- MACD
- AVTX 0.03
- IOBT 0.01
- Stochastic Oscillator
- AVTX 11.96
- IOBT 43.10
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.